These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11519868)

  • 1. BRCA1 and BRCA2: to test or not to test.
    Brandt RT; Lynch HT
    Breast Cancer Res Treat; 2001 May; 67(2):187-8. PubMed ID: 11519868
    [No Abstract]   [Full Text] [Related]  

  • 2. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
    Spannuth WA; Thaker PH; Sood AK
    Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The decision to test in women receiving genetic counseling for BRCA1 and BRCA2 mutations.
    Kelly K; Leventhal H; Andrykowski M; Toppmeyer D; Much J; Dermody J; Marvin M; Baran J; Schwalb M
    J Genet Couns; 2004 Jun; 13(3):237-57. PubMed ID: 15604634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary breast/ovarian cancer--pitfalls in genetic counseling.
    Dagan E; Gershoni-Baruch R
    Clin Genet; 2001 Oct; 60(4):310-3. PubMed ID: 11683778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can a computer-based system be used to educate women on genetic testing for breast cancer susceptibility?
    Schwartz MD; Tercyak KP; Peshkin BN; Valdimarsdottir H
    Nat Clin Pract Oncol; 2005 Jan; 2(1):24-5. PubMed ID: 16264852
    [No Abstract]   [Full Text] [Related]  

  • 6. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations.
    Chopra I; Kelly KM
    J Health Commun; 2017 Feb; 22(2):143-152. PubMed ID: 28112991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
    Marchina E; Fontana MG; Speziani M; Salvi A; Ricca G; Di Lorenzo D; Gervasi M; Caimi L; Barlati S
    Oncol Rep; 2010 Dec; 24(6):1661-7. PubMed ID: 21042765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary breast cancer in Jews.
    Rubinstein WS
    Fam Cancer; 2004; 3(3-4):249-57. PubMed ID: 15516849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.
    Kauff ND; Perez-Segura P; Robson ME; Scheuer L; Siegel B; Schluger A; Rapaport B; Frank TS; Nafa K; Ellis NA; Parmigiani G; Offit K
    J Med Genet; 2002 Aug; 39(8):611-4. PubMed ID: 12161607
    [No Abstract]   [Full Text] [Related]  

  • 11. Sporadic breast cancer among relatives of BRCA mutation carriers.
    Allweis TM; Sagi M; Peretz T
    Genet Med; 2005; 7(9):655-6. PubMed ID: 16301869
    [No Abstract]   [Full Text] [Related]  

  • 12. Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.
    Phillips KA; Warner E; Meschino WS; Hunter J; Abdolell M; Glendon G; Andrulis IL; Goodwin PJ
    Clin Genet; 2000 May; 57(5):376-83. PubMed ID: 10852372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer. A risky business--assessing breast cancer risk.
    Levy-Lahad E; Plon SE
    Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
    Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
    Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
    Smith M; Fawcett S; Sigalas E; Bell R; Devery S; Andrieska N; Winship I
    Fam Cancer; 2008; 7(2):119-24. PubMed ID: 17636421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critics question BRCA2 patent decision in Europe.
    Steimle S
    J Natl Cancer Inst; 2005 Sep; 97(18):1326. PubMed ID: 16174851
    [No Abstract]   [Full Text] [Related]  

  • 17. BRCA1 and BRCA2 cancer risks.
    Antoniou AC; Pharoah PD; Easton DF; Evans DG
    J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
    [No Abstract]   [Full Text] [Related]  

  • 18. Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics.
    Eccles DM
    Ann Oncol; 2004; 15 Suppl 4():iv133-8. PubMed ID: 15477297
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
    Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
    Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    Printz C
    Cancer; 2020 Feb; 126(4):693. PubMed ID: 31995244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.